Adherence to denosumab for the treatment of osteoporosis in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study

2020 ◽  
pp. 1-4
Author(s):  
Masanori Nakayama ◽  
Takefumi Furuya ◽  
Eisuke Inoue ◽  
Eiichi Tanaka ◽  
Katsunori Ikari ◽  
...  
2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 364.2-364
Author(s):  
K. Oh ◽  
O. Namiki ◽  
Y. Toyoshima ◽  
K. Inagaki ◽  
K. Kanbe ◽  
...  

2016 ◽  
Vol 43 (8) ◽  
pp. 1475-1479 ◽  
Author(s):  
Yosuke Hattori ◽  
Toshihisa Kojima ◽  
Atsushi Kaneko ◽  
Daihei Kida ◽  
Yuji Hirano ◽  
...  

Objective.To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).Methods.All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.Results.The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.Conclusion.Concomitant MTX contributes to the longterm efficacy of ADA therapy.


2018 ◽  
Vol 41 (9) ◽  
pp. 1414-1422 ◽  
Author(s):  
Jun Hakamata ◽  
Yuko Kaneko ◽  
Mikiko Shimizu ◽  
Kunihiro Yamaoka ◽  
Junya Maruyama ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document